Design of CONQUEST, a novel, randomized, placebo-controlled, Phase 2b platform clinical trial to investigate new treatments for patients with early active systemic sclerosis with interstitial lung disease
Authors
- Shervin Assassi (ORCID: https://orcid.org/0000-0002-8059-9978)
- Wade W. Benton (ORCID: https://orcid.org/0000-0003-1511-7490)
- K. Maslova
- Gregory Gordon
- Toby M. Maher (ORCID: https://orcid.org/0000-0001-7192-9149)
- Dinesh Khanna (ORCID: https://orcid.org/0000-0003-1412-4453)
- Luke Evnin
- Juergen Steffgen
Institutions
- University of Southern California (US)
- Boehringer Ingelheim (Germany) (DE)
- University of Michigan (US)
- Sanofi (United States) (US)
- Scleroderma Foundation (US)
- Imperial College London (GB)
- The University of Texas Health Science Center at Houston (US)
Publication Details
- Journal
- Journal of Scleroderma and Related Disorders
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1177/23971983241278079
- Citations
- 8
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 3.40
Funders
- Boehringer Ingelheim
- Vanderbilt University
- Cleveland Clinic
- Johns Hopkins University
- University of Pittsburgh
- Georgetown University
- McGill University
- Hospital for Special Surgery
- McGovern Medical School
- Imperial College London
- University College London
- University of Leeds
- Universiteit Leiden
- Università degli Studi di Firenze
- Jewish General Hospital
- Universitätsspital Zürich